Skip to main content
CMG Pharmaceutical Co., Ltd. logo

CMG Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 058820 ISIN · KR7058820002 KO Manufacturing
Filings indexed 165 across all filing types
Latest filing 2024-12-30 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 058820

About CMG Pharmaceutical Co., Ltd.

http://www.cmgpharma.co.kr

CMG Pharmaceutical Co., Ltd. is a pharmaceutical company specializing in the development of advanced drug delivery systems. The company's core competency is its Oral Thin Film (OTF), or Orally Dissolving Film (ODF), technology platform. This technology is used to develop improved new drugs, new formulations, and combination therapies designed to enhance patient convenience and efficacy. The company's portfolio includes prescription medications and general pharmaceuticals. As an affiliate of CHA Health Systems, CMG Pharmaceutical is actively engaged in research and development, managing a pipeline of drug candidates and conducting clinical trials.

Recent filings

Filing Released Lang Actions
전환가액의조정
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing from CMG Pharmaceutical regarding the adjustment of the conversion price of convertible bonds due to a decline in market price. This type of disclosure, which details changes to capital structure instruments (convertible debt), falls under the category of Capital/Financing Update.
2024-12-30 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement regarding the setting of a record date and shareholder register closure for the purpose of holding an upcoming Annual General Meeting (AGM). It does not contain the full AGM materials or proxy statements, but rather serves as a formal regulatory notice of the meeting preparation. Given the nature of the announcement as a regulatory filing regarding corporate governance procedures, it fits best under the RNS category.
2024-12-12 Korean
분기보고서 (2024.09)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for CMG Pharmaceutical Co., Ltd. for the period from January 1, 2024, to September 30, 2024. It contains comprehensive financial data, business descriptions, management analysis, and audit information, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2024
2024-11-13 Korean
투자판단관련주요경영사항 (데핍조(Depipzo) 미국 식품의약국(FDA) 품목허가 신청)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from CMG Pharmaceutical regarding the submission of a New Drug Application (NDA) for 'Depipzo' to the US FDA. It is a specific corporate announcement regarding a material business event (regulatory filing for product approval). Since it does not fit into specific categories like financial reports, dividends, or board changes, and is a formal regulatory disclosure, it falls under the RNS (Regulatory Filings) category.
2024-10-15 Korean
반기보고서 (2024.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-Annual Report) for CMG Pharmaceutical, covering the period from January 1, 2024, to June 30, 2024. It contains detailed financial information, management discussion, and operational data, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2024
2024-08-13 Korean
증권발행결과(자율공시)
Capital/Financing Update Classification · 100% confidence The document is a formal announcement regarding the results of a securities issuance (specifically a private placement of convertible bonds). It details the issuance amount, payment date, and the nature of the securities. This falls under the category of capital and financing updates as it relates to the company's capital structure and fundraising activities.
2024-07-11 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.